Theralink Technologies (Theralink Technologies) Effective Interest Rate on Debt % : 83.72% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Theralink Technologies's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $18.22 Mil. Theralink Technologies's average total debt for the quarter that ended in Dec. 2023 was $21.76 Mil. Therefore, Theralink Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 83.72%.

Theralink Technologies Effective Interest Rate on Debt % Historical Data

The historical data trend for Theralink Technologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies Effective Interest Rate on Debt % Chart

Theralink Technologies Annual Data

Trend

Feb14

Feb15

Dec16

Dec17

Dec18

Dec19

Sep20

Sep21

Sep22

Sep23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

65.86

1.60

27.78

45.12

140.09

Theralink Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															198.95	371.34	202.44	126.60	83.72

Competitive Comparison of Theralink Technologies's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Theralink Technologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralink Technologies's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Effective Interest Rate on Debt % falls into.

Theralink Technologies Effective Interest Rate on Debt % Calculation

Theralink Technologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Sep. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Sep. 2022 )	+	Total Debt (A: Sep. 2023 ))	/ count )
=	-1 * -16.907	/	( (4.375	+	19.762)	/ 2 )
=	-1 * -16.907	/	12.0685
=	140.09 %

where

	Total Debt (A: Sep. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.944	+	1.431
=	4.375

	Total Debt (A: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.131	+	18.631
=	19.762

Theralink Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * -18.216	/	( (19.762	+	23.755)	/ 2 )
=	-1 * -18.216	/	21.7585
=	83.72 %

where

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.131	+	18.631
=	19.762

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.117	+	22.638
=	23.755

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Theralink Technologies (OTCPK:THER) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Theralink Technologies Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralink Technologies (Theralink Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401

Website

https://www.theralink.com

Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.

Executives

Danica Holley	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz	director	15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors	director	1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin	director, officer: Chief Executive Officer	HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc	10 percent owner	1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett	officer: Chief Executive Officer	230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb	director	PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman	10 percent owner, officer: Chief Operating Officer-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme	director, 10 percent owner, officer: Global Operations GM-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman	director	C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: CFO & President	549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head	director, officer: Chief Executive Officer	6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817